Alimera Sciences, Inc. (ALIM) News
Filter ALIM News Items
ALIM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALIM News Highlights
- For ALIM, its 30 day story count is now at 2.
- Over the past 11 days, the trend for ALIM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RES are the most mentioned tickers in articles about ALIM.
Latest ALIM News From Around the Web
Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial OfficerRussel Skibsted 2MB Russell Skibsted, CFO of Alimera Sciences Russell Skibstead Hi-Res Russell Skibsted, CFO of Alimera Sciences ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President |
Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call TranscriptAlimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript November 14, 2022 Alimera Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.75 EPS, expectations were $-0.4. Operator: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Third Quarter 2022 Financial Results and Corporate Update Conference Call. at […] |
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan AgreementATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced that it has agreed to an amendment to its existing loan and security agreement with its debt facility partner, SLR Investment Corp (“SLR”) to extend the interest-only period through March 31, 2023 with the possibility |
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN AdministrationData was included in scientific programming at the annual meeting of The Retina Society ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces findings from a recent meeting |
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® AdministrationData was included in scientific programming at the annual meeting of The Retina SocietyATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces findings from a recent meeting where data demonstrated a high level of agreement among retina specialists on the role of inflammation in |
7 Stocks That Could Implode at Any MomentAlthough it’s a party-pooper topic, the vagaries of the market dictates that investors should be aware of these stocks to sell. |
Alimera Sciences Third Quarter 2022 Earnings: Misses ExpectationsAlimera Sciences ( NASDAQ:ALIM ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.6m (up 12% from 3Q... |
H.C. Wainwright Sticks to Its Buy Rating for Alimera (ALIM)In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Alimera (ALIM - Research Report), with a price target of $9.00. The company's shares closed yesterday at $4.88.According to TipRanks, Chen is an analyst with an average return of -28.1% and a 24.40% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals.Alimera has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.See today’s best-performing stocks on TipRanks >>Based on Alimera's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $14. |
Alimera Sciences: Q3 Earnings SnapshotALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Monday reported a loss of $5.3 million in its third quarter. On a per-share basis, the Alpharetta, Georgia-based company said it had a loss of 75 cents. The eye drug developer posted revenue of $13.6 million in the period. The … |
Alimera Sciences Announces Third Quarter 2022 Financial ResultsATLANTA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2022. Alimera will host a conference call today at 9:00 a.m. EST to discuss these results. |